Agenus Inc., an immuno-oncology company with a pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines, has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody. Agenus will receive a $20 million payment with the dosing of the first patient.   This Phase 1 dose escalation study is designed to evaluate the safety, tolerability, and preliminary clinical activ...